rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk.
|
23029260 |
2012 |
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
rs104894226
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
rs1057519766
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
rs1057519802
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.
|
18971950 |
2009 |
rs1057520009
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma.
|
28196522 |
2017 |
rs1057520014
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
rs1114167651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
rs112445441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk.
|
23029260 |
2012 |
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
rs11536889
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined whether or not genetic variations in toll-like receptor 1 (rs5743551, -7202GQ>A), toll-like receptor 2 (rs7656411, 22215G>T), and toll-like receptor 4 (rs11536889, +3725G>C) affected transplant outcomes in a cohort of 365 patients who underwent unrelated HLA-matched bone marrow transplantation (for hematologic malignancies through the Japan Marrow Donor Program.
|
28484092 |
2017 |
rs121434596
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
rs1217691063
|
|
|
0.020 |
GeneticVariation |
BEFREE |
MTHFR C677T polymorphism may be a good predictor for MTX toxicity in adult hematological malignancies.
|
27270164 |
2016 |
rs1217691063
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Differential effects of the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) on hematological malignancies among Latinos: a meta-analysis.
|
31188929 |
2019 |
rs121913390
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
rs121913393
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
rs121913506
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
An update on molecular genetics of gastrointestinal stromal tumours.
|
16731599 |
2006 |
rs121913506
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
An update on molecular genetics of gastrointestinal stromal tumours.
|
16731599 |
2006 |
rs121913507
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.
|
29643855 |
2018 |
rs121913512
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
|
11526490 |
2001 |
rs121913615
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
|
16834459 |
2006 |
rs121913682
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.
|
29643855 |
2018 |
rs121918453
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
rs121918454
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |